ArticleCase reports in hematology2026
Polycythemia Vera Transforming to Pure Erythroid Leukemia: A Diagnostic Mimic of Thrombotic Microangiopathy With High-Risk TP53 Biology.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemic transformation of polycythemia vera (PV) to acute myeloid leukemia (AML) with a predominantly erythroid blast population is rare and carries a poor prognosis, particularly when driven by a TP53 mutation. We report a 55-year-old man with JAK2 V617F-positive PV, previously noted on surveillance biopsy to harbor a TP53 mutation and Grade 2 marrow fibrosis, who presented three years later with pancytopenia, schistocytosis, hyperferritinemia, hypofibrinogenemia, and altered mental status. The initial clinical presentation raised concern for thrombotic thrombocytopenic purpura (TTP), while the presence of rare circulating blasts and coagulopathy also prompted consideration of acute promyelocytic leukemia (APML). Empiric plasma exchange, corticosteroids, and all-trans retinoic acid were initiated. ADAMTS13 activity and PML-RARA FISH subsequently returned negative. The patient deteriorated with multiorgan failure and expired before leukemia-directed therapy could be initiated. Postmortem bone marrow results demonstrated greater than 90% erythroid blasts with TP53 protein overexpression, a TP53 p.C238Y mutation (VAF 66%), and a triploid karyotype with 7p and 19p abnormalities, consistent with pure erythroid leukemia (PEL) arising from an antecedent myeloproliferative neoplasm. This case highlights the diagnostic challenges posed by overlapping clinical features of TTP and APML, including limitations in immunophenotypic assignment of the erythroid lineage. Importantly, it provides a longitudinally documented example of a TP53 mutation detected three years before overt transformation and describes a previously unreported presentation mimicking both TTP and APML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.